Squamous Cell Carcinoma of the Head and Neck  >>  sonolisib (PX 866)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sonolisib (PX 866) / Pfizer
NCT01252628: Phase 1 and 2 Study of PX-866 and Cetuximab

Checkmark In pts with metastatic CRC or recurrent/metastatic SCCHN
Jun 2014 - Jun 2014: In pts with metastatic CRC or recurrent/metastatic SCCHN
Checkmark P1 data
Nov 2011 - Nov 2011: P1 data
Completed
1/2
178
US, Canada
PX-866 (SCCHN), Cetuximab (SCCHN), Erbitux, PX-866 (CRC), Cetuximab (CRC)
Cascadian Therapeutics Inc.
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
11/13
01/14
NCT01204099: Study of PX-866 and Docetaxel in Solid Tumors

Checkmark PX-866 + docetaxel combo trial for locally advanced, recurrent or metastatic SCCHN
Jan 2015 - Jan 2015: PX-866 + docetaxel combo trial for locally advanced, recurrent or metastatic SCCHN
Checkmark Top-line data from PX-866 + docetaxel trial for NSCLC
Aug 2013 - Aug 2013: Top-line data from PX-866 + docetaxel trial for NSCLC
Checkmark P2 data - ASCO
More
Completed
1/2
223
US, Canada
Docetaxel, taxotere, PX-866
Cascadian Therapeutics Inc.
Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
12/13
02/14

Download Options